Athira Pharma (ATHA) began trading on the Nasdaq on Fri 18 Sept 20

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.

Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 63
• Incorporated in 2011 
• Headquartered in Bothell, Washington
• https://www.athira.com

IPOs this week : October 12 - 16, 20 (wk 42)

 IPOs expected to price

• Codiak BioSciences (CDAK), 
• Array Technologies (ARRY), 
• MINISO Group (MNSO), 
• Spinal Elements (SPEL), 
• Jupiter Wellness (JUPW) and 
• Aziyo Biologics (NASDAQ:AZYO) 

IPO lockup expirations

• Adaptive Biotechnologies (NASDAQ:ADPT), 
• Atreca (NASDAQ:BCEL), 
• HeadHunter Group (NASDAQ:HHR) and 
• Postal Realty Trust (NYSE:PSTL) on October 14. 

IPO quiet period expirations

• Metacrine (NASDAQ:MTCR), Outset Medical (NASDAQ:OM) and Dyne Therapeutics (NASDAQ:DYN) on October 12, as well as 
• Athira Pharma (NASDAQ:ATHA) on October 13.